Imovax Polio

Inactivated poliovirus vaccine, the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is used to prevent poliomyelitis caused by poliovirus types 1, 2 and 3 in individuals at risk of infection.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across global markets, with a focus on timely delivery and cold‑chain management where required.

Imovax Polio is an inactivated poliovirus vaccine used in the prevention of poliomyelitis, a viral infection of the nervous system. - Poliomyelitis (polio): provides active immunity to prevent infection by poliovirus types 1, 2 and 3. - Travel to endemic regions: protects travelers against polio infection when visiting areas with ongoing transmission. - Outbreak control: employed in mass vaccination campaigns to halt community spread of poliovirus.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema that resolves within a few days. - Low‑grade fever: transient temperature rise occurring within 24‑48 hours. - Irritability (in children): temporary fussiness or restlessness. - Headache: mild headache reported in some recipients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare neurologic events reported post‑vaccination. - Guillain‑Barré syndrome: extremely rare autoimmune neuropathy. - Hypotension: sudden drop in blood pressure following injection. - Severe allergic reaction to vaccine components: includes angioedema or bronchospasm.

Precautions should be observed when administering Imovax Polio. - Allergy assessment: avoid use in individuals with severe hypersensitivity to any vaccine component. - Immunocompromised patients: evaluate risk‑benefit, although the vaccine is inactivated. - Pregnancy: consult a healthcare provider; data are limited, use only if clearly needed. - Concurrent vaccines: may be given with other vaccines at separate sites, but monitor for increased reactogenicity. - Age considerations: follow recommended immunisation schedule for infants, children, and adults. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential interactions with other medicines or biologics should be considered. Major Interactions (Avoid): - Immunoglobulin therapy: may reduce vaccine immunogenicity; avoid simultaneous administration. - Live viral vaccines: schedule appropriately; do not give within 4 weeks of each other. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may mask fever, monitor temperature post‑vaccination. - Immunosuppressive drugs: may diminish antibody response, assess serologic protection. - Other injectable vaccines: co‑administration is generally safe but observe for heightened local reactions.